Fab Entech

FAB’ENTECH is a privately-owned company developing and manufacturing polyclonal immunotherapies to address situations of emergency. After having successfully developed Fabenflu®, a treatment of H5N1 infections in human, Fab’entech is now focusing on intoxications with antidote candidates in the fields of biodefense (in collaboration with the French Army) and drug intoxication (in collaboration with a private industrial partner). Based on this strategy, which will make the company become sustainable by 2022, Fab’entech is also currently securing a Series-B fundraising. Today, Fab’entech wants to leverage on these preliminary successes, and is therefore seeking new industrial partners to collaborate on the development of its biodefense asset, and on the development of antidotes in additional indications as well.